*Article* **Ectopic Leptin Production by Intraocular Pancreatic Islet Organoids Ameliorates the Metabolic Phenotype of** *ob/ob* **Mice**

**Barbara Leibiger \*, Tilo Moede , Ismael Valladolid-Acebes, Meike Paschen, Montse Visa , Ingo B. Leibiger and Per-Olof Berggren \***

> The Rolf Luft Research Center for Diabetes and Endocrinology, Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska Sjukhuset L1:03, 17176 Stockholm, Sweden<EMAIL_ADDRESS>(T.M<EMAIL_ADDRESS>(I.V.-A<EMAIL_ADDRESS>(M.P<EMAIL_ADDRESS>(M.V<EMAIL_ADDRESS>(I.B.L.)

**\*** Correspondence<EMAIL_ADDRESS>(B.L<EMAIL_ADDRESS>(P.-O.B.)

**Abstract:** The pancreatic islets of Langerhans consist of endocrine cells that secrete peptide hormones into the blood circulation in response to metabolic stimuli. When transplanted into the anterior chamber of the eye (ACE), pancreatic islets engraft and maintain morphological features of native islets as well as islet-specific vascularization and innervation patterns. In sufficient amounts, intraocular islets are able to maintain glucose homeostasis in diabetic mice. Islet organoids (pseudo-islets), which are formed by self-reassembly of islet cells following disaggregation and genetic manipulation, behave similarly to native islets. Here, we tested the hypothesis that genetically engineered intraocular islet organoids can serve as production sites for leptin. To test this hypothesis, we chose the leptin-deficient *ob/ob* mouse as a model system, which becomes severely obese, hyperinsulinemic, hyperglycemic, and insulin resistant. We generated a Tet-OFF-based beta-cell-specific adenoviral expression construct for mouse leptin, which allowed efficient transduction of native beta-cells, optical monitoring of leptin expression by co-expressed fluorescent proteins, and the possibility to switch-off leptin expression by treatment with doxycycline. Intraocular transplantation of islet organoids formed from transduced islet cells, which lack functional leptin receptors, to *ob/ob* mice allowed optical monitoring of leptin expression and ameliorated their metabolic phenotype by improving bodyweight, glucose tolerance, serum insulin, and C-peptide levels.

**Keywords:** pancreatic islets; leptin; exocytosis; tissue-engineering; in vivo imaging; metabolism; diabetes; β-cell; viral transduction; transplantation

#### **1. Introduction**

Pancreatic islets of Langerhans are micro-organs that form the endocrine part of the pancreas. They consist of endocrine alpha-, beta-, delta-, epsilon- and PP-cells, that produce and secrete glucagon, insulin, somatostatin, ghrelin, and pancreatic polypeptide, respectively. The fenestrated islet blood vessels allow for an efficient exchange of bloodderived factors stimulating these cells as well as the immediate release of the secreted hormones into the blood circulation. Importantly, these characteristics are maintained when pancreatic islets are transplanted into the anterior chamber of the eye, ACE [1]. In fact, transplantation of a sufficient number of islets to the ACE (75–300 islets in mice) showed that these islet grafts are capable of maintaining glycaemia in streptozotocintreated diabetic mice ([1], reviewed in [2]). Islet organoids (also called pseudo-islets) that are formed by self-reassembly of islet cells following disaggregation and genetic manipulation, for example by adenoviral-mediated ectopic gene expression [3,4], behave similarly to native islets. Because of these features, we wanted to test the hypothesis that genetically engineered intraocular islet organoids can serve as production sites for blood-born proteins/peptides as a novel treatment strategy. To test this hypothesis, we chose the *ob/ob* mouse as a disease model. *Ob/ob* mice lack functional leptin, which is an

**Citation:** Leibiger, B.; Moede, T.; Valladolid-Acebes, I.; Paschen, M.; Visa, M.; Leibiger, I.B.; Berggren, P.-O. Ectopic Leptin Production by Intraocular Pancreatic Islet Organoids Ameliorates the Metabolic Phenotype of *ob/ob* Mice. *Metabolites* **2021**, *11*, 387. https://doi.org/10.3390/ metabo11060387

Academic Editors: Melkam Kebede, Belinda Yau and Dawn Belt Davis

Received: 13 April 2021 Accepted: 11 June 2021 Published: 14 June 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Copyright:** © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).

adipocyte-produced peptide hormone, and develop a very pronounced phenotype based, among others, on their extreme hyperphagia. After weaning, they become severely obese, hyperinsulinemic, hyperglycemic, and insulin resistant (reviewed in [5]). Treating these mice with peripherally administered leptin reverses [6,7] or ameliorates this phenotype in a dose-dependent manner [8]. Ectopic expression of leptin via gene therapy approaches by either injecting virus-encoded leptin constructs [9,10] or transplanting engineered leptinexpressing cells [11,12] improves the metabolic phenotype of *ob/ob* mice even further. Because leptin acts in concert with insulin as anorexic stimuli in the central nervous system (reviewed in [13]), we decided to genetically engineer insulin-producing beta-cells to become production sites for leptin. This allowed us to test the hypothesis whether ectopic leptin production by islet organoids in the ACE ameliorates the metabolic phenotype of *ob/ob* mice.

#### **2. Results**

#### *2.1. Generation of a Tet-OFF-Based Beta-Cell Specific Adenoviral Expression Construct for Mouse Leptin and Its In Vitro Assessment*

When designing the expression construct for mouse leptin, we considered the following points: We wanted (1) leptin to be expressed in pancreatic beta-cells, (2) to be able to reduce/turn-off leptin expression if necessary, (3) to optically monitor the activity of the expression construct by fluorescence microscopy, and (4) an adenoviral-based expression construct for efficient transduction of native beta-cells. As a result, we generated an adenoviral vector, vAd-RIP-leptin-OFF, that contains two expression cassettes that are positioned in opposite directions and are separated by a 'transcription-block' sequence to allow independent expression (Figure 1a). The first expression cassette allows rat insulin-1 promoter-driven expression of the synthetic transcription factor tTA (Tet-OFF) and the green fluorescent protein ZsGreen in pancreatic beta-cells. The second expression cassette consists of a TRE-tight promoter-driven mouse leptin-IRES-mCherry cassette. Binding of tTA to the TRE-tight promoter induces the expression of leptin and the red fluorescent protein mCherry in beta-cells. Addition of doxycycline inhibits binding of tTA and turns-off the expression of the two proteins. The IRES-element in the two expression cassettes allows the co-expression of tTA with ZsGreen and leptin with mCherry. Hence, 'green' and 'red' serve as visual read-outs for the expression of tTA and leptin in beta-cells, respectively. For in vitro assessment of the expression construct, we used organoids created from transduced islets cells of B6.BKS(D)-Leprdb/J (*db/db*) mice. Organoids from the same preparations were also used for the transplantations. The detection of green and red fluorescence by laser-scanning confocal microscopy in beta-cells of the islet organoids verified that both expression cassettes were active in the same cells (Figure 1b,c). The islet organoids secreted leptin into the culture medium, the secretion was glucose-dependent: 7.02 ± 1.76 pg/organoid/h at 3 mM glucose vs. 12.94 ± 2.83 pg/organoid/h at 16 mM glucose (stimulation index 16 versus 3 mM glucose: 1.93 ± 0.14).

#### *2.2. Ectopic Leptin Production by Islet Organoid Grafts in the ACE Ameliorates the Metabolic Phenotype of ob/ob Mice*

To test whether intraocular leptin production by islet organoids affects the metabolic phenotype of *ob/ob* mice, we considered the following points. Because leptin deficiency after weaning leads to a rapid development of the *ob/ob* phenotype, including strong beta-cell proliferation in both the native in situ islets as well as in islets transplanted to the ACE and leptin treatment decelerates this process [14], we decided to treat *ob/ob* mice with daily intraperitoneal injections of leptin (1.5 µg/g bodyweight/day) immediately after their arrival from the vendor until 4 weeks after transplantation of the islet organoid grafts, i.e., until their full engraftment. Moreover, because leptin is discussed in the literature to have a negative effect on insulin secretion [15], we decided to avoid the potential negative feed-back of beta-cell produced leptin on the organoids by generating them from islets of leptin receptor-deficient mice, i.e., islets from *db/db* mice with a B6 genetic background (B6.BKS(D)-Leprdb/J) to match the B6 background of the *ob/ob* recipient mice (B6.Cg-

Lepob/J). Hence, we isolated islets from *db/db* mice, disaggregated them, transduced the islets cells with vAd-RIP-leptin-OFF and generated islet organoids by self-reassembly. *Metabolites* **2021**, *11*, x FOR PEER REVIEW 3 of 16

**Figure 1.** In vitro characterization of leptin-expressing islet organoids. (**a**) Schematic illustration of vAd-RIP-leptin-OFF. The rat insulin-1 promoter (rIns-1) drives expression of the synthetic transcription factor tTA and the green fluorescent protein ZsGreen in pancreatic beta-cells. The TRE-tight promoter drives expression of mouse leptin (mLeptin) and the red fluorescent protein mCherry. The two expression cassettes are separated by a transcription blocker sequence (TB). Binding of tTA to the TRE-tight promoter induces in the absence of doxycycline the expression of leptin and mCherry, while addition of doxycycline turns-off the expression of the two proteins. IRES-elements in the cassettes ensures stoichiometric expression of the two proteins under the same promoter. (**b**) Representative maximum projection of a 3D-stack of leptinexpressing islet organoids, obtained by confocal imaging, cultured for 4 weeks in vitro (1st set of experiments), showing reflection, expression of ZsGreen, mCherry and their overlay. Scale bar: 50 µm. (**c**) Representative maximum projection of a 3D-stack of leptin-expressing islet organoids, obtained by confocal imaging, cultured for 4 weeks in vitro (2nd set of experiments), showing reflection, expression of ZsGreen, mCherry and their overlay. Scale bar: 50 µm. *2.2. Ectopic Leptin Production by Islet Organoid Grafts in the ACE Ameliorates the Metabolic*  **Figure 1.** In vitro characterization of leptin-expressing islet organoids. (**a**) Schematic illustration of vAd-RIP-leptin-OFF. The rat insulin-1 promoter (rIns-1) drives expression of the synthetic transcription factor tTA and the green fluorescent protein ZsGreen in pancreatic beta-cells. The TRE-tight promoter drives expression of mouse leptin (mLeptin) and the red fluorescent protein mCherry. The two expression cassettes are separated by a transcription blocker sequence (TB). Binding of tTA to the TRE-tight promoter induces in the absence of doxycycline the expression of leptin and mCherry, while addition of doxycycline turns-off the expression of the two proteins. IRES-elements in the cassettes ensures stoichiometric expression of the two proteins under the same promoter. (**b**) Representative maximum projection of a 3D-stack of leptin-expressing islet organoids, obtained by confocal imaging, cultured for 4 weeks in vitro (1st set of experiments), showing reflection, expression of ZsGreen, mCherry and their overlay. Scale bar: 50 µm. (**c**) Representative maximum projection of a 3D-stack of leptin-expressing islet organoids, obtained by confocal imaging, cultured for 4 weeks in vitro (2nd set of experiments), showing reflection, expression of ZsGreen, mCherry and their overlay. Scale bar: 50 µm.

*Phenotype of ob/ob Mice* To test whether intraocular leptin production by islet organoids affects the metabolic phenotype of *ob/ob* mice, we considered the following points. Because leptin deficiency after weaning leads to a rapid development of the *ob/ob* phenotype, including strong betacell proliferation in both the native in situ islets as well as in islets transplanted to the ACE and leptin treatment decelerates this process [14], we decided to treat *ob/ob* mice with daily intraperitoneal injections of leptin (1.5 µg/g bodyweight/day) immediately after their arrival from the vendor until 4 weeks after transplantation of the islet organoid grafts, i.e., until their full engraftment. Moreover, because leptin is discussed in the literature to have a negative effect on insulin secretion [15], we decided to avoid the potential negative feedback of beta-cell produced leptin on the organoids by generating them from islets of leptin receptor-deficient mice, i.e., islets from *db/db* mice with a B6 genetic background In a first set of experiments (Figure A1a) we transplanted 130 leptin-expressing *db/db* islet organoids into the ACE of female *ob/ob* mice (*n =* 3, see Figure 2a,b) that were treated with leptin from 15 d before transplantation until 28 d after transplantation and used leptin-treated (for the same time period) female *ob/ob* mice that were not transplanted with islet organoids as a control group (*n =* 3). To use non-transplanted leptin-treated *ob/ob* mice as controls was based on previous observations showing extreme growth of non-leptin expressing intraocular islet grafts in *ob/ob* mice, which required premature termination of experiments for ethical reasons. Inspection of islet organoids kept in vitro (Figure 1b) as well as organoids transplanted to the ACE in vivo (Figure 2b) showed expression of both green and red fluorescent proteins, indicating that both the tTA-IRES-ZsGreen and mLeptin-IRES-mCherry expression cassettes were expressed in beta-cells. While we did

not observe a difference in the bodyweight of mice between the two groups (Figure 2c), we observed an improvement in glucose tolerance starting 10 d after stopping leptin treatment, which became significant 25 d after stopping leptin treatment in the transplanted group (Figures 2d and A1b). *Metabolites* **2021**, *11*, x FOR PEER REVIEW 5 of 16

**Figure 2.** In vivo characterization of leptin-expressing islet organoids from the first set of experiments. (**a**) Photograph of the eye containing the leptin-expressing islet organoid graft (red arrow) 9 weeks after transplantation. (**b**) Maximum projection of a 3D-stack of a leptin-expressing islet organoid graft (red arrow) obtained by confocal imaging 9 weeks after transplantation; (**ba**) reflection, (**bb**) mCherry fluorescence, (**bc**) ZsGreen fluorescence, (**bd**) overlay image; scale bar 500 µm. (**c**) Bodyweight of transplanted and control mice over the entire period of the experiment. (**d**) Area under the curve (AUC) for ipGTT of transplanted and control mice over the entire period of the experiment. (**e**) Fasting blood glucose of transplanted and control mice over the entire period of the experiment. (**f**) Plasma insulin levels of transplanted and control mice at the end of the experiment. (**g**) Plasma C-peptide levels of transplanted and control mice at the end of the experiment. (**d**,**e**) \* *p* < 0.05. (**c**–**g**) *n =* 3. **Figure 2.** In vivo characterization of leptin-expressing islet organoids from the first set of experiments. (**a**) Photograph of the eye containing the leptin-expressing islet organoid graft (red arrow) 9 weeks after transplantation. (**b**) Maximum projection of a 3D-stack of a leptin-expressing islet organoid graft (red arrow) obtained by confocal imaging 9 weeks after transplantation; (**ba**) reflection, (**bb**) mCherry fluorescence, (**bc**) ZsGreen fluorescence, (**bd**) overlay image; scale bar 500 µm. (**c**) Bodyweight of transplanted and control mice over the entire period of the experiment. (**d**) Area under the curve (AUC) for ipGTT of transplanted and control mice over the entire period of the experiment. (**e**) Fasting blood glucose of transplanted and control mice over the entire period of the experiment. (**f**) Plasma insulin levels of transplanted and control mice at the end of the experiment. (**g**) Plasma C-peptide levels of transplanted and control mice at the end of the experiment. (**d**,**e**) \* *p* < 0.05. (**c**–**g**) *n =* 3.

Moreover, in the group transplanted with leptin-producing organoids we observed

35 d after stop of leptin treatment, a trend towards lower plasma insulin (Figure 2f) and

Moreover, in the group transplanted with leptin-producing organoids we observed a trend towards a decrease in fasting blood glucose (Figure 2e), which was significant at 35 d after stop of leptin treatment, a trend towards lower plasma insulin (Figure 2f) and insulin C-peptide (Figure 2g) levels, both measured at the end of the experiment. Finally, we detected leptin in the aqueous humor (11.375 ± 3.211 ng/mL) at the end of the experiment in the transplanted group, while no leptin was detectable in the control group. No leptin was detectable in the blood plasma from both groups, as the levels in the transplanted group were likely below the detection limit of the ELISA kit used.

In a second set of experiments (Figure A2a) we transplanted 200 leptin-expressing *db/db* islet organoids into the ACE of female *ob/ob* mice that were treated with leptin from 7 d before until 28 d after transplantation (*n =* 7, Figure 3a,b) and used leptin-treated female *ob/ob* mice that were not transplanted with islet organoids as a control group (*n =* 5).

Inspection of islet organoids kept in vitro (Figure 1c) as well organoids transplanted to the ACE in vivo (Figure 3b) showed expression of both green and red fluorescent proteins, indicating that both the tTA-IRES-ZsGreen and mLeptin-IRES-mCherry expression cassettes were expressed in beta-cells. Importantly in this experiment, mice that were transplanted with leptin-producing organoids showed a significant difference in bodyweight from 15 d after stop of leptin treatment (Figure 3c). We observed a significant improvement in ipGTT starting from 19 d after stop of leptin treatment (Figures 3d and A2b). Moreover, we observed a decrease in fasting blood glucose (Figure 3e, significant on days 19 and 68 after stop of leptin treatment), a significant decrease in plasma insulin (from day 14 after stop of leptin, Figure 3f) and a significant decrease in plasma C-peptide levels (from day 8 after stop of leptin, Figure 3g) in the group transplanted with leptin-producing organoids. Finally, we detected leptin in the aqueous humor (6.05 ± 2.91 ng/mL) of the transplanted group at the end of the experiment while no leptin was detectable in the control group. The values of leptin in plasma of the transplanted group were 185.52 ± 10.73 pg/mL between day 8 after stop of leptin treatment and the end of the experiment (Figure A2c). No leptin was detectable in plasma from the control group.

#### *2.3. Doxycycline Treatment Stops Ectopic Leptin Expression*

Three animals of the transplanted group were treated with doxycycline (five intraperitoneal injections of 50 µg dox/kg/mouse over 10 days) to switch-off leptin production from the transplanted organoids. In grafts of these animals no mCherry fluorescence was detectable (Figure 4(bc)) and no leptin expression could be detected by immunohistochemistry (Figure 4(dc)) at the end of the experiment. Expression of only green (Figure 4(bb)), but not red (Figure 4(bc)), fluorescent protein in the graft of doxycycline-treated animals indicates that only the tTA-IRES-ZsGreen cassette was expressed in beta-cells and the expression of the mLeptin-IRES-mCherry cassette was switched-off. In grafts of non-doxycycline treated animals both mCherry and leptin expression were detectable (Figure 4(ac,cc)). More importantly, no leptin was measurable in the aqueous humor of doxycycline-treated animals (*n =* 3).

insulin C-peptide (Figure 2g) levels, both measured at the end of the experiment. Finally, we detected leptin in the aqueous humor (11.375 ± 3.211 ng/mL) at the end of the experiment in the transplanted group, while no leptin was detectable in the control group. No leptin was detectable in the blood plasma from both groups, as the levels in the trans-

In a second set of experiments (Figure A2a) we transplanted 200 leptin-expressing *db/db* islet organoids into the ACE of female *ob/ob* mice that were treated with leptin from 7 d before until 28 d after transplantation (*n =* 7, Figure 3a,b) and used leptin-treated female *ob/ob* mice that were not transplanted with islet organoids as a control group (*n =* 5).

planted group were likely below the detection limit of the ELISA kit used.

**Figure 3.** In vivo characterization of leptin-expressing islet organoids from the second set of experiments. (**a**) Photograph of the eye containing the leptin-expressing islet organoid graft (red arrow) 6 weeks after transplantation. (**b**) Maximum **Figure 3.** In vivo characterization of leptin-expressing islet organoids from the second set of experiments. (**a**) Photograph of the eye containing the leptin-expressing islet organoid graft (red arrow) 6 weeks after transplantation. (**b**) Maximum projection of a 3D-stack of a leptin-expressing islet organoid graft (red arrow) obtained by confocal imaging 12 weeks after transplantation; (**ba**) reflection, (**bb**) mCherry fluorescence, (**bc**) ZsGreen fluorescence, (**bd**) overlay image; scale bar 300 µm. (**c**) Bodyweight, (**d**) Area under the curve (AUC) for ipGTT, (**e**) Fasting blood glucose, (**f**) Plasma insulin levels and (**g**) Plasma C-peptide levels of transplanted and control mice over the period of the experiment. (**c**–**g**) \* *p* < 0.05, \*\* *p* < 0.01, \*\*\* *p* < 0.001; *n =* 7 for transplanted and 5 for control group.

**Figure 4.** Characterization of leptin-expressing islet organoid grafts from animals treated with doxycycline, removed at the end of the experiment. (**a**) Fluorescent microscopy image of a leptin-expressing islet organoid graft from transplanted non-doxycycline-treated animal; (**aa**) DAPI staining; (**ab**) ZsGreen fluorescence; (**ac**) mCherry fluorescence; (**ad**) overlay. (**b**) Fluorescent microscopy image of a leptin-expressing islet organoid graft from transplanted doxycycline-treated animal; (**ba**) DAPI staining, (**bb**) ZsGreen fluorescence, (**bc**) mCherry fluorescence, (**bd**) overlay. (**c**) Immunohistochemistry image of a leptin-expressing islet organoid graft from transplanted non-doxycycline treated animal; (**ca**) DAPI staining, (**cb**) C-peptide staining, (**cc**) leptin staining, (**cd**) overlay. (**d**) Immunohistochemistry image of a leptin-expressing islet organoid graft from transplanted doxycycline treated animal; (**da**) DAPI staining, (**db**) C-peptide staining, (**dc**) leptin staining, (**dd**) overlay. (**a**–**d**) All scale bars 50 µm. **Figure 4.** Characterization of leptin-expressing islet organoid grafts from animals treated with doxycycline, removed at the end of the experiment. (**a**) Fluorescent microscopy image of a leptin-expressing islet organoid graft from transplanted non-doxycycline-treated animal; (**aa**) DAPI staining; (**ab**) ZsGreen fluorescence; (**ac**) mCherry fluorescence; (**ad**) overlay. (**b**) Fluorescent microscopy image of a leptin-expressing islet organoid graft from transplanted doxycycline-treated animal; (**ba**) DAPI staining, (**bb**) ZsGreen fluorescence, (**bc**) mCherry fluorescence, (**bd**) overlay. (**c**) Immunohistochemistry image of a leptin-expressing islet organoid graft from transplanted non-doxycycline treated animal; (**ca**) DAPI staining, (**cb**) C-peptide staining, (**cc**) leptin staining, (**cd**) overlay. (**d**) Immunohistochemistry image of a leptin-expressing islet organoid graft from transplanted doxycycline treated animal; (**da**) DAPI staining, (**db**) C-peptide staining, (**dc**) leptin staining, (**dd**) overlay. (**a**–**d**) All scale bars 50 µm.

#### **3. Discussion 3. Discussion**

We have previously shown that the ACE as a transplantation site allows i) optical/microscopic monitoring of graft vascularization and function), ii) monitoring of potential pharmacological intervention (systemic or ocular/intraocular treatment), and iii) the possibility to remove the graft if needed (e.g., by iridectomy). Moreover, hormones secreted by intraocular pancreatic islets are capable of maintaining glucose homeostasis in a diabetic recipient (reviewed in [2]). In this proof-of-concept study we aimed to test whether genetically engineered islet organoids can serve as production sites for non-islet bloodborn peptides/proteins, here leptin, and take advantage of the above-listed properties of the ACE as a transplantation site. We designed an adenoviral vector for beta-cell specific expression of mouse leptin that in addition allowed to monitor the activity of the expres-We have previously shown that the ACE as a transplantation site allows (i) optical/microscopic monitoring of graft vascularization and function), (ii) monitoring of potential pharmacological intervention (systemic or ocular/intraocular treatment), and (iii) the possibility to remove the graft if needed (e.g., by iridectomy). Moreover, hormones secreted by intraocular pancreatic islets are capable of maintaining glucose homeostasis in a diabetic recipient (reviewed in [2]). In this proof-of-concept study we aimed to test whether genetically engineered islet organoids can serve as production sites for non-islet blood-born peptides/proteins, here leptin, and take advantage of the above-listed properties of the ACE as a transplantation site. We designed an adenoviral vector for beta-cell specific expression of mouse leptin that in addition allowed to monitor the activity of the expression cassettes by fluorescence microscopy and to switch-off leptin expression by

doxycycline treatment. Expression of leptin in beta-cells brought the potential advantage of glucose-regulated leptin secretion. In addition to the glucose-regulated route of secretion, pancreatic beta-cells are also equipped for continuous release of proteins [16]. We used leptin-expressing islet organoids generated from *db/db* mouse pancreatic islets. Here, all islet cells lack the expression of the functional/signaling leptin receptor and thus do not allow a potential feedback action of secreted leptin on the organoid graft. We chose *ob/ob* mice as recipients, because these mice lack expression of functional leptin and thus develop a severe metabolic phenotype that is easy to monitor, i.e., increased bodyweight, hyperglycemia, and hyperinsulinemia. By transplanting leptin-expressing islet organoids to the ACE we could show that leptin, secreted by the organoids, ameliorates the metabolic phenotype of the *ob/ob* mice. Transplanted mice showed significantly reduced bodyweight, improved glucose tolerance, decreased fasting blood glucose and significant decreased plasma insulin and C-peptide levels. The food intake of these animals was not measured because it would require single animal housing to get reliable results, which was not possible due to the limited number of experimental animals and limitations set by our ethical permits. IpITTs could not be performed due to restrictions of our ethical permits not allowing us to fast the animals more than two times per month. Ectopically expressed leptin was detectable in the aqueous humor and plasma of transplanted mice, whereas no leptin was detected in non-transplanted mice. It is noteworthy that despite the additional beta-cell volume due to the islet organoid grafts, we observed a decrease in serum insulin and C-peptide levels as a result of the ectopic leptin expression. When some of the animals in our study were treated with doxycycline, the co-expression of leptin and mCherry was stopped, demonstrating that the ectopic leptin expression can be switched-off in vivo by the Tet-OFF part of the adenoviral construct.

Our results are comparable to those obtained from *ob/ob* mice that were transplanted with engineered and encapsulated gut-derived K-cells to the peritoneal cavity [11] or with engineered leptin-secreting skin grafts [12].

Although we achieved long-term action of leptin, secreted from the transplanted islet organoids, the effect on glucose metabolism started to fade by the end of the experiment. This can be due to multiple reasons including among others immune response to adenoviral-transduced cells or the transgene [9,18], leading to development of anti-leptin antibodies [9] and increased demand for insulin from transplanted islet organoids, which can lead to hypertrophy and cell proliferation, thereby "diluting out" the leptin-producing cells [6,19]. The limited longevity of adenovirus-mediated expression has been discussed in the past [20,21].

Our study with relative low numbers of animals shows encouraging results. Future work is needed to confirm our preliminary conclusions. In the future, it will be possible to generate islet organoids from genetically engineered stem-cell derived material. This will not only help to overcome the shortage of supply of primary pancreatic islets but will allow engineering the cellular components for an optimized protein production site.

In summary, we have demonstrated that ectopic leptin production by genetic engineered islet organoids, transplanted into the ACE, ameliorates the obese and diabetic phenotype in leptin-deficient *ob/ob* mice. Using the ACE as the transplantation site allowed for optical monitoring of ectopic gene expression by the use of co-expressed fluorescent proteins and gives the safety potential to remove the intraocular graft by for example iridectomy.

In conclusion, our data provide a proof-of-concept that genetically engineered islet organoids can serve, as entire micro-organs, as factories for non-islet blood-born peptides in high enough concentrations to have a physiological function, here exemplified by the production of leptin.

#### **4. Materials and Methods**

#### *4.1. Animals*

Female B6.Cg-Lepob/J (*ob/ob*) mice at 4 weeks of age and B6.BKS(D)-Leprdb/J (*db/db*) mice at 8 weeks of age were purchased from Jackson Laboratories (Bar Harbour, ME, USA). Both mouse strains share a C57BL/6J (B6) background. After delivery, the mice were allowed to adapt to the animal facility for 1 week before the start of the experiment. All mice were group-housed on a 12/12-h dark/light cycle with free access to food (chow diet R70 from Lantmännen, Kimstad, Sweden) and water. All experiments were performed in accordance with the Karolinska Institutet's guidelines for the care and use of animals in research and were approved by the institute's Animal Ethics Committee.

#### *4.2. Leptin Treatment of ob/ob Mice*

*Ob/ob* mice were treated daily with one intraperitoneal injection of recombinant human leptin protein (1.5 µg/g bodyweight, R&D Systems, Minneapolis, MN, USA) from the day of arrival until 4 weeks after transplantation.

#### *4.3. Expression Vector Construction*

The mouse leptin cDNA was obtained from pCMV6.mouse leptin (#MC208876, Ori-Gene, Rockville, MD, USA) and subcloned into pTRE-tight (Clontech, Takara, Mountain View, CA, USA) to create pTRE-tight.mLeptin. Next, we inserted an IRES-mCherry sequence downstream of the mLeptin cDNA to obtain pTRE-tight.mLeptin-IRES-mCherry. To create pENTR.TRE-tight.mLeptin-IRES-mCherry/RIP1.DsRed2 we exchanged in pENTR. rbGK.EGFP/RIP1.DsRed2 [22] the rbGK.EGFP cassette by TRE-tight.mLeptin-IRES-mCherry. Next, we exchanged in pENTR.TRE-tight.mLeptin-IRES-mCherry/RIP1.DsRed2 the DsRed cDNA by the TetOFF-IRES-ZsGreen cassette obtained from pTetOFF-Dual (Green) (Clontech, Takara, Mountain View, CA, USA), thus generating pENTR.TRE-tight.mLeptin-IRESmCherry/RIP1.TetOFF-IRES-ZsGreen. All constructs were verified by DNA sequence analysis and leptin expression was verified by Simple Western. The TRE-tight.mLeptin-IRES-mCherry/RIP1.TetOFF-IRES-ZsGreen cassette was transferred into the promoter-less adenovirus plasmid pAd/PL-DEST (Thermo Fisher Scientific, Waltham, MA, USA) by the Gateway technique. The ViraPower Adenoviral Expression System (Thermo Fisher Scientific, Waltham, MA, USA) was used to generate a replication-deficient adenovirus called vAd-RIP-leptin-OFF, which was used for transduction of cells.

#### *4.4. Isolation of Pancreatic Islets*

Islets were isolated from B6.BKS(D)-Leprdb/J (*db/db*) mice. Islets were prepared from mice by duct injection of collagenase (F. Hoffmann-La Roche, Basel, Switzerland) and were handpicked under a stereomicroscope MZ6 (Leica Microsystems, Wetzlar, Germany) after digestion. Thereafter, islets were cultured in RPMI-1640 medium (RPMI medium, Gibco, Thermo Fisher Scientific, Waltham, MA, USA), with a final concentration of 10% heatinactivated fetal bovine serum, 2 mM glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin (all from Gibco, Thermo Fisher Scientific, Waltham, MA, USA) at 5% CO<sup>2</sup> and 37 ◦C.

#### *4.5. Islet Organoid Production*

The islets were collected into 1.5 mL Eppendorf tubes (250 islets/tube), digested with accutase (Sigma-Aldrich, St. Louis, MO, USA) for 10 min at 37 ◦C and centrifuged at 500 rpm. The islet cells were transduced with 4 <sup>×</sup> <sup>10</sup><sup>6</sup> plaque forming units/mL of the leptin encoding adenovirus in suspension culture dishes for 1h in RPMI medium at 5% CO<sup>2</sup> and 37 ◦C and then washed two times with an excess of RPMI medium to get rid of the adenovirus. 2500 islet cells were seeded into each well of Nunclon Sphera 96U Bottom plates (Thermo Scientific, Leicestershire, UK). Islet organoids formed over a time of 5 days, after which the organoids were transferred to suspension culture dishes.

#### *4.6. In Vitro Imaging of Intraocular Islet Organoids*

An inverted laser scanning confocal microscope (TCS SP8, Leica Microsystems, Wetzlar, Germany) was used to image islet organoids as 3-dimensional stacks with a 3-µm step size. ZsGreen fluorescent protein was excited at 488 nm, and the fluorescence was detected at 505–535 nm, mCherry was excited at 561 nm, and fluorescence was detected at 580–650 nm. Backscatter signal (reflection) from the 561-nm excitation was collected at 555–565 nm.

#### *4.7. Leptin Secretion from Islet Organoids In Vitro*

Islet organoids were cultured in vitro in suspension culture dishes in RPMI medium. For glucose-stimulated leptin secretion measurements the organoids were placed into 4-well-plate (Nunc, Thermo Fisher Scientific, Waltham, MA, USA) suspension dishes containing RPMI medium with 3 mM glucose for 1.5 h. After that, the organoids were first placed into new wells containing medium with 3 mM glucose for 30 min and then later into new wells containing 16 mM glucose for 30 min. Then the organoids were returned into suspension culture dishes containing normal RPMI medium for continued culture. The medium from the 4-well-plate wells was collected into Eppendorf tubes, centrifuged for 1 min to pellet possible organoid fragments. The supernatants were collected into fresh tubes and kept at −20 ◦C until analysis.

#### *4.8. Transplantation of Islet Organoids into the ACE*

The islet organoids were transplanted into the ACE of three (first set of experiments) and seven (second set of experiments) *ob/ob* recipients, using a technique previously described in [23]. Briefly, under anesthesia, organoids were transplanted into the ACE with a glass cannula after generating a puncture in the cornea with a 27-gauge needle. Great care was taken to avoid bleeding and damage to the iris. Each mouse of the transplanted group received 100 organoids/eye. Mice were injected subcutaneous with Temgesic (0.1 mL/kg; RB Pharmaceuticals, Berkshire, UK) for postoperative analgesia. Three *ob/ob* mice (first set of experiments) and five *ob/ob* mice (second set of experiments) were used as controls and were not transplanted.

#### *4.9. In Vivo Imaging of Intraocular Islet Organoid Grafts*

Islet organoid grafts were imaged in vivo, beginning 9 weeks after transplantation. An upright laser scanning confocal microscope (TCS SP5, Leica Microsystems, Wetzlar, Germany), equipped with a long-distance, water-dipping objective (HXC-APO10x/0.30 NA, Leica Microsystems, Wetzlar, Germany) and a custom-built stereotaxic head holder, allowing positioning of the mouse eye containing the engrafted islets toward the objective, was used. Viscotears (Thea Nordic, Örebro, Sweden) was used as an immersion liquid between the eye and the objective, and isoflurane was used to anesthetize the mice during in vivo imaging. Grafts were imaged as 3-dimensional stacks with 3-µm step size. ZsGreen fluorescent protein was excited at 488 nm, and the fluorescence was detected at 505–535 nm. mCherry was excited at 561 nm, and fluorescence was detected at 580–650 nm. Backscatter signal (reflection) from the 561-nm excitation was collected at 555–565 nm. After imaging, the mice were allowed to recover from anesthesia. Additionally, beginning 6 weeks after transplantation, overview images of the grafts were obtained using a digital camera connected to a Leica M60 stereomicroscope (Leica Microsystems, Wetzlar, Germany) while the mice were under anesthesia.

#### *4.10. Doxycycline Treatment of Animals*

Three animals of the transplanted group were treated with doxycycline (Clontech, Takara, Mountain View, CA, USA) in order to stop leptin production from the islet organoid grafts. Sterile doxycycline hydrochloride, dissolved in PBS, was administered intraperitoneally 5 times over 10 days (50 µg/kg/mouse), starting on day 53 after stopping leptin treatment.

#### *4.11. Body Weight and Fasting and Non-Fasting Blood Glucose*

Body weight was determined before 9 am with full access to food. Fasting blood glucose was measured after 6 h denial of food. Non-fasting blood glucose was measured at 4 pm with full access to food.

#### *4.12. Intraperitoneal Glucose Tolerance Test (ipGTT)*

To determine glucose tolerance, blood glucose levels were measured in mice that were unfed for 6 h at basal state (0 min) and at 10, 30, 60, and 120 min after glucose injection (2 g/kg bodyweight intraperitoneally, dissolved in PBS). The results were depicted as the area under the curve (AUC) of the ipGTT. Glucose concentrations were measured with the Accu-Chek Aviva monitoring system (F. Hoffmann-La Roche, Basel, Switzerland). If blood glucose concentrations exceeded the detection limit of the glucose meter, the limit value of 33.3 mM was used as value for the determination of the AUC of the ipGTT.

#### *4.13. Plasma and Aqueous Humor Samples*

Blood samples were taken in the mornings from non-fasted animals and collected into Microvette CB300 EDTA/PK100 tubes (Sarstedt, Nürnbrecht, Germany), centrifuged to gain blood plasma, and preserved at −20 ◦C until use. Aqueous humor samples were obtained at the end of the experiment and kept at −20 ◦C until use.

#### *4.14. Insulin and C-Peptide Measurements*

Ultrasensitive mouse ELISA kits (Crystal Chem, Elk Grove Village, IL, USA) were used to analyze insulin and C-peptide levels in the plasma.

#### *4.15. Leptin Measurements*

Leptin was measured in cell culture medium, blood plasma, and aqueous humor samples using the Mouse/Rat Leptin Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, USA).

#### *4.16. Tissue Extraction and Sectioning*

Mice were anesthetized with isoflurane and sacrificed by cervical dislocation. Eyes were extracted and fixed with 4% paraformaldehyde for 1 week. Before cryopreservation, the eyes were processed with a sucrose gradient (10–30% (wt/vol) sucrose in PBS containing 0.01% (wt/vol) sodium azide and 0.02% (wt/vol) bacitracin, embedded in OCT-Compound (Tissue-Tek, Sakura Finetek, Torrance, CA, USA), frozen on dry ice, and preserved at −80 ◦C until use. Then, 20 µm thick cryosections of the anterior part of the eye were collected on SuperFrost Plus microscope slides (VWR International, Radnor, PA, USA) and kept at −20 ◦C until use.

#### *4.17. Immunofluorescence in Eye Sections*

For immunostaining, eye sections were equilibrated to room temperature, washed, blocked, and incubated with the primary antibodies, goat anti m-leptin (R&D Systems, Minneapolis, MN, USA) and rabbit anti-C-peptide (Cell Signaling, Danvers, MA, USA) in the presence of 0.1% Triton X-100 and 10% serum. After washing, secondary antibodies, anti-goat Alexa633, and anti-rabbit Alexa594, respectively (Thermo Fisher Scientific, Waltham, MA, USA), were applied, and mounting with medium containing DAPI for nuclear counterstaining (Thermo Fisher Scientific, Waltham, MA, USA) was performed after repeated washing. Imaging was performed using a confocal laser scanning microscope (Leica TCS SP8, Leica Microsystems, Wetzlar, Germany) with the following settings: DAPI excitation 405 nm, detection 450–470 nm; ZsGreen excitation 488 nm, detection 500–525 nm; mCherry excitation 548 nm, detection 560–580 nm; Alexa 594 (C-peptide staining) excitation 594 nm, detection 600–620 nm and Alexa 633 (leptin staining) excitation 633 nm, detection 640–680 nm. To avoid spectral overlap imaging was performed using in-between-frames sequential imaging.

#### *4.18. Statistics*

The values are expressed as means ± SEM. A 2-sided, unpaired t test was used to determine statistical significance among different treatment groups. Statistical significance was determined as follows: \* *p* < 0.05, \*\* *p* < 0.01 and \*\*\* *p* < 0.001. Origin 2015 64-bit (OriginLab, Northampton, MA, USA) and Excel (Microsoft, Redmond, WA, USA) were used for statistical analyses.

#### **5. Conclusions**

Our data provide a proof-of-concept that genetically engineered islet organoids can serve as production sites for blood-born proteins/peptides.

**Author Contributions:** The authors contributed to the study in the following matter: conceptualization, P.-O.B., I.B.L., B.L. and T.M.; methodology, T.M., M.P., B.L., M.V. and I.V.-A.; validation, T.M., I.V.-A., B.L. and I.B.L.; formal analysis, T.M. and I.V.-A.; investigation, I.B.L., B.L. and T.M.; resources, P.-O.B. and I.B.L.; data curation, T.M. and I.V.-A.; writing—original draft preparation, B.L. and I.B.L.; writing—review and editing, P.-O.B., I.B.L. and B.L.; visualization, T.M. and B.L.; supervision, B.L. and I.B.L.; project administration, I.B.L.; funding acquisition: P.-O.B. and I.B.L. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by Karolinska Institutet, Swedish Research Council, The Erling-Persson Family Foundation, the Novo Nordisk Foundation, the Stichting af Jochnick Foundation, Diabetesfonden (Sweden), Scandia Insurance Company Limited, the Diabetes Research and Wellness Foundation, the Berth von Kantzows Foundation, the Strategic Research Program in Diabetes at Karolinska Institutet, the European Research Council grant number ERC-2018-AdG 834860 EYELETS, the Swedish Foundation for Strategic Research and the Knut and Alice Wallenbergs Foundation.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki, and the animal experiments were approved by the Institutional Review Board (or Ethics Committee) of KAROLINSKA INSTITUTET (ethical permit numbers N34/16, approved on 23 February 2016 and 19462–2017, approved on 8 February 2018).

#### **Informed Consent Statement:** Not applicable.

**Conflicts of Interest:** P.-O.B. is cofounder and CEO of the biotech company Biocrine AB. B.L. and I.B.L. are consultants for the same company. T.M., M.P., M.V. and I.V.A. have no relationships or activities that might bias, or be perceived to bias, this work. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

*Metabolites* **2021**, *11*, x FOR PEER REVIEW 14 of 16

#### **Appendix A**

**Figure A1.** Additional information related to Figure 2. (**a**) Timeline of the first set of experiments. (**b**) Individual traces from the ipGTTs summarized as AUC in Figure 2d. Data are expressed as mean ± SEM. Data points that include saturated

**Figure A1.** *Cont.*

glucose measurements that were set to 33.3 mM are labeled with #. \* *p* < 0.05; \*\**p* < 0.01; *n =* 3.

**Figure A1.** Additional information related to Figure 2. (**a**) Timeline of the first set of experiments. (**b**) Individual traces from the ipGTTs summarized as AUC in Figure 2d. Data are expressed as mean ± SEM. Data points that include saturated glucose measurements that were set to 33.3 mM are labeled with #. \* *p* < 0.05; \*\**p* < 0.01; *n =* 3. **Figure A1.** Additional information related to Figure 2. (**a**) Timeline of the first set of experiments. (**b**) Individual traces from the ipGTTs summarized as AUC in Figure 2d. Data are expressed as mean ± SEM. Data points that include saturated glucose measurements that were set to 33.3 mM are labeled with #. \* *p* < 0.05; \*\* *p* < 0.01; *n =* 3. *Metabolites* **2021**, *11*, x FOR PEER REVIEW 15 of 16

**Figure A2.** *Cont.*

planted mice over the period of the experiment, *n = 3–7*.

**Figure A2.** Additional information related to Figure 3. (**a**) Timeline of the second set of experiments. (**b**) Individual traces from the ipGTTs summarized as AUC in Figure 3d. Data are expressed as mean ± SEM. Data points that include saturated glucose measurements are labeled with #. \* *p* < 0.05; \*\* *p* < 0.01;\*\*\* *p* < 0.001; *n =* 7 for transplanted and 5 for control group. (**c**) Plasma leptin levels of trans-

**Figure A2.** Additional information related to Figure 3. (**a**) Timeline of the second set of experiments. (**b**) Individual traces from the ipGTTs summarized as AUC in Figure 3d. Data are expressed as mean ± SEM. Data points that include saturated glucose measurements are labeled with #. \* *p* < 0.05; \*\* *p* < 0.01;\*\*\* *p* < 0.001; *n =* 7 for transplanted and 5 for control group. (**c**) Plasma leptin levels of transplanted mice over the period of the experiment, *n = 3–7*. **Figure A2.** Additional information related to Figure 3. (**a**) Timeline of the second set of experiments. (**b**) Individual traces from the ipGTTs summarized as AUC in Figure 3d. Data are expressed as mean ± SEM. Data points that include saturated glucose measurements are labeled with #. \* *p* < 0.05; \*\* *p* < 0.01; \*\*\* *p* < 0.001; *n =* 7 for transplanted and 5 for control group. (**c**) Plasma leptin levels of transplanted mice over the period of the experiment, *n* = 3–7.

#### **References**


**5. The modern lace braiding machine**

The modern lace braiding machine is a direct descendent of the Barmen lace machines. The modern lace braiding machine has been continually improved; as witnessed in the numerous European, Japanese, and international patents. Some notable improvements include electromagnetic actuation of driver plates which allow electronic pattern control and computerized design to operate seamlessly without Jacquard punch paper. The electronic control eliminated the need for a mechanical Jacquard mechanism. Improvements in machine materials have increased the wear resistance and life of components. Certain mechanical features of the modern lace braiding machine protect the components and its lace product during production. For example, if the yarn breaks during production, the machine will automatically shut off as the bobbin carrier shorts an electrical switch so that the lace fabric can be saved and the broken yarn can be repaired by simply tying a knot. If this feature were not available, each time a yarn broke, the whole lace fabric would have to be discarded. A second feature is the construction of clutches out of a low-cost plastic material. If certain components fail to function perfectly, the clutch will fail before machine damage occurs. These inexpensive clutches can be replaced relatively easily and quickly. These two protective features are essential for industrial lace braiding but they limit the size and type of yarn that can be used.

Presently many of the modern machines are produced by Asian manufacturers who are in proximity to the textile manufacturing locations, although the Krenzler Company still manufactures lace braiding machines in Germany [16]. The machine evaluated in this research is manufactured in South Korea and clearly has its engineering origins from the Barmen lace machine. Considering improvements in the Barmen lace braiding machine during the last 30 years and the fact that many lace braiding machines are now manufactured outside of Germany, we refer to these machines as modern lace braiding machines. We acknowledge that the modern lace braiding machines originated from the Barmen lace machines.

**Figure 5** is an engineering rendering of the modern lace braiding machine evaluated during this research. **Figure 6** illustrates the bobbin spindle actuation assembly. Spindle cradles are used to move yarns with the driving plates. The solenoid actuates the plastic cam which in turn lifts the plastic fork and plastic clutch and engages the driver plate allowing the spur gear to rotate the spindle cradles and perform the basic cross and twist motions on the yarns. After 180 degrees of rotation, the cam pushes against the inactive solenoid and a compression spring forces the fork and clutch to the resting position while spindle cradles and bobbins remain stationary.

#### **5.1. Bobbin spindles (carriers)**

Another notable difference of the Barmen lace braiding machine is the beat-up mechanism. This mechanism is akin to the weaving machine reed used to control fabric density. The beatup mechanism is found in the center of the machine and consists of a dome with slits to allow reciprocating action of knife blades to compact the yarns following the corresponding beating motion. The blades are deployed as even and odd groups, according to the driver plate and spindle motions. These important advances over the Maypole braiding machine provide the

The driver plates are positioned as a series of overlapping circles about the machine radius. The driver plate geometry is symmetric about two orthogonal axes with concave and convex regions. For a plate to rotate adjacent plates are required to remain stationary. Adjacent concave regions precisely permit the moving convex spindle cradle to pass without interference. This motion serves as the primary mechanism for imparting motion to the spindles and ultimately the yarn. In the same way as the traditional braiding machine, two different motions

Lace machines have been employed with a variety of materials, both natural and synthetic fibers, in the production of fancy lace and other apparel products. Marenzana [15] describes the use of Rayon fiber with lace braiding machines. Surface fiber treatments, known as sizing, may improve the lace braiding process as well as resin-fiber compatibility in subsequent composite manufacture. The use of high performance fibers such as those commonly found

The modern lace braiding machine is a direct descendent of the Barmen lace machines. The modern lace braiding machine has been continually improved; as witnessed in the numerous European, Japanese, and international patents. Some notable improvements include electromagnetic actuation of driver plates which allow electronic pattern control

ability to produce complex and irregular fabric structures.

**Figure 4.** Schematic view of lace braiding machine.

64 Engineered Fabrics

in composite materials has not been reported in the literature.

**5. The modern lace braiding machine**

are required to pass a spindle.

**4.3. Known materials used**

Another important component is the bobbin spindle. Commonly referred to as carriers, they control the tension in the braiding yarn as well as allowing the release of new material during braiding. See **Figure 7** for the following operational details. The yarn is unwound from the bobbin and passed through an initial eyelet making a 90-degree bend where it continues until a second eyelet is located which also requires a 90-degree bend toward the spindle center where another 90 degree turn over a ratcheting pawl is required. The yarn now travels down the center of the spindle tube i.e. bobbin axis of revolution where a tension spring with eyelet requires a 180 degree turn. Finally, the yarn moves up the tube where a final ceramic eyelet allows the yarn to reach the fabric formation zone.

**Figure 5.** CAD drawing of modern lace braiding machine.

**6. Analysis of machine for manufacture of structural composite**

Lace braiding technology has been demonstrated in the manufacture of intricate and decorative fabrics for more than a century. If lace braiding machines are suitable for handling large high strength yarns such as aramid and even carbon fiber prepregs, it was thought that the structures might be suitable for use as planar and 3-D space trusses. An evaluation of a modern lace braiding machine is performed on the typical execution to determine if braided composite strength-to-weight ratio could be improved by utilizing a lace braiding technology. A modern lace braiding machine incorporating a computer controllable electro-mechanical yarn interlacing system was purchased to test the proposition that it might be used to more efficiently orient and interlace yarns to create a truss-like pre-form in either a flat or cylindrical form [17]. **Figure 8** is an example of a CAD model for a proposed composite tube manu-

Lace Braiding Machines for Composite Preform Manufacture

http://dx.doi.org/10.5772/intechopen.82256

67

**Figure 9** shows the initial lace fabric preform made with a modern lace braiding machine during the evaluation and research phase of this work. The small white yarns are cotton. **Figure 10** shows a flat lace manufactured on a modern lace braiding machine made from

**Table 1** denotes a list of advantages of the modern lace and braiding machine.

**pre-forms**

**Figure 7.** Bobbin spindle (carrier).

factured with a lace braiding machine.

larger twisted yarns.

**Figure 6.** Main bobbin actuation assembly (front and rear views).

Lace Braiding Machines for Composite Preform Manufacture http://dx.doi.org/10.5772/intechopen.82256 67

**Figure 7.** Bobbin spindle (carrier).

**Figure 5.** CAD drawing of modern lace braiding machine.

66 Engineered Fabrics

**Figure 6.** Main bobbin actuation assembly (front and rear views).